BBIO vs KARD: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

BBIO is the larger of the two ($15.03B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta 0.94). KARD is the smaller challenger ($1.12B), also expected to post a loss next year: more room to run, but more to prove. If you believe in growth, BBIO fits: analysts expect its revenue to rise 52% next year, against 0% for KARD. If you believe KARD's main driver (Late-stage cardiovascular pipeline) pays off sooner, KARD fits.

BBIO vs KARD: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricBBIOKARDWhat it tells you
Market cap$15.03B$1.12BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-282.25-2.88Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Price vs 52-week range47% of range2% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Before you buy: how BBIO and KARD affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BBIO and KARD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BBIO and KARD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does BridgeBio Pharma (BBIO) do?

BridgeBio Pharma (NASDAQ: BBIO) is a Palo Alto-based biopharmaceutical company focused on genetic diseases and genetically driven cancers. Its commercial engine is Attruby (acoramidis), an oral TTR stabilizer approved by the FDA in November 2024 for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive and often underdiagnosed heart condition. Attruby competes in a market long dominated by Pfizer's tafamidis franchise, and BridgeBio has been rapidly building prescriber and patient uptake since launch.

Full BBIO guide

What does Kardigan (KARD) do?

Kardigan, Inc. (Nasdaq: KARD) is a clinical-stage precision cardiovascular therapeutics company based in Princeton, New Jersey, founded in 2023 and formerly known as EnCarda. It was created by former executives of MyoKardia, the team behind mavacamten (Camzyos), the hypertrophic cardiomyopathy drug that led to Bristol Myers Squibb's roughly $13 billion acquisition of MyoKardia. Kardigan is developing three late-stage candidates that target the underlying biology of specific heart conditions where treatments are limited: danicamtiv (a cardiac myosin activator in-licensed from BMS) for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension. It pairs these programs with the Prolaio AI and real-world-data platform, branded as Cardiac Intelligence, to sharpen trial design.

Full KARD guide

BBIO vs KARD: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • BBIO drivers: Attruby (acoramidis) commercial ramp; Pipeline diversification and 2026 filings.
  • KARD drivers: Late-stage cardiovascular pipeline; MyoKardia pedigree and BMS-sourced asset.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is concentration: Attruby is BridgeBio's only approved commercial product, so near-term performance is highly dependent on a single therapy in a competitive market. For KARD, kardigan is pre-revenue and deeply loss-making, so its value depends on clinical trial outcomes that remain years away and could fail.

BBIO or KARD: which should you pick?

If the story you believe is BBIO's (Attruby (acoramidis) commercial ramp), BBIO is the more direct way to own it; if it is KARD's (Late-stage cardiovascular pipeline), KARD is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BBIO and KARD guides.

BBIO vs KARD: the full fundamentals

BBIO. BBIO trades at about 16 times trailing revenue, a multiple that rests on continued Attruby growth and pipeline launches, since the company still loses money. Third-quarter revenue nearly tripled year over year and the loss per share beat estimates for the first time in four quarters, and the shares are roughly flat in 2026 after a 13% rise over the past month. The 20 analysts tracked by Yahoo Finance hold an average target near $107, above the November 20 close of about $77, with the BBP-418 FDA decision due by November 27.

KARD. Kardigan generates no product revenue and funds a growing research budget, producing a net loss of about $58.6 million in Q3 2026 (reduced by a $21.8 million milestone fair-value benefit) and roughly $287 million over the trailing twelve months. Its valuation reflects pipeline potential, not current financials: at about $1.13 billion, the market cap is roughly 1.9 times the ~$591 million of cash, so investors are assigning around $540 million to three mid- and late-stage programs whose main readouts now fall between the second quarter and the second half of 2027. Analysts expect a loss of about $4.53 per share for 2026 and $4.17 for 2027.

Headline figures (approximate, November 2026): BBIO shows revenue (ttm) ~$946M, revenue (q3 2026) ~$353M, up ~193% year over year, q3 2026 eps vs estimate ~-$0.42 vs ~-$0.56, net income (ttm) ~-$592M; KARD shows revenue (ttm) ~$0 (pre-commercial), net loss (ttm) ~-$287M, net loss (q3 2026) ~-$58.6M (incl. ~$21.8M milestone fair-value benefit), eps (q3 2026) -$0.64 vs ~-$1.04 expected.

The bottom line: BBIO vs KARD

BBIO and KARD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BBIO and KARD exposure against your real portfolio. It is not an investment adviser.

Wondering how BBIO or KARD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about BridgeBio Pharma

Ask Walnut's AI anything about BBIO and see how it fits what you own.

FAQ

What is the difference between BBIO and KARD?

+

BridgeBio Pharma (NASDAQ: BBIO) is a Palo Alto-based biopharmaceutical company focused on genetic diseases and genetically driven cancers. Kardigan, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is BBIO or KARD the better stock?

+

Neither is universally better. BBIO is the larger incumbent; KARD is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BBIO or KARD?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BBIO and KARD?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BBIO vs KARD?

+

BBIO: The dominant risk is concentration: Attruby is BridgeBio's only approved commercial product, so near-term performance is highly dependent on a single therapy in a competitive market. Pfizer's entrenched tafamidis franchise and Alnylam's vutrisiran (Amvuttra) are well-funded rivals fighting for the same patients. Any FDA delay, rejection, request for more data, or narrower-than-expected label for BBP-418 (decision due by November 27, 2026), infigratinib, or encaleret would push out the diversification timeline. The company is still unprofitable, with a trailing net loss near $592 million and roughly $3.38 billion of debt, and although the third-quarter loss beat estimates, the three quarters before it came in wider than expected. Pricing pressure, slower diagnosis growth, or a valuation that still embeds heavy optimism (about 16 times trailing sales) could all weigh on the shares. KARD: Kardigan is pre-revenue and deeply loss-making, so its value depends on clinical trial outcomes that remain years away and could fail. Its S-1 disclosures included going-concern language tied to pre-IPO cash, and while the IPO extended the runway into 2028, the company will likely need to raise more capital and could dilute shareholders. Any negative or delayed data from danicamtiv, ataciguat, or tonlamarsen could sharply reduce the stock, and a post-IPO lock-up expiration may add selling pressure. The shares have already shown that volatility: they fell below the $16.00 IPO price and closed near $12.04 on November 20, 2026, about 42% lower over three months. The November 2026 decision to read ataciguat at week 48 and the slower tonlamarsen enrollment push two of three readouts into the second half of 2027, extending the wait and the cash burn before the main catalysts. Contingent milestone liabilities tied to in-licensed assets can also swing reported losses in both directions, as a $43.5 million fair-value charge in the second quarter of 2026 and a $21.8 million benefit in the third showed. It also competes with larger, better-capitalized cardiovascular players.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BBIO or KARD; figures are approximate and dated (as of November 2026). Verify current data before investing.